Mezagitamab Completed Phase 1 Trials for Systemic Lupus Erythematosus / Coronavirus Disease 2019 (COVID‑19) Other
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Completed | Other | 1 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT03724916 | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) |